Basic Fun, Blue Planet Software develop Tetris keychain carabiners
SOUTHAMPTON, Pa. Tetris keychain carabiners are slated to roll out worldwide next fall.
The keychain carabiners will be created through Basic Fun’s line of dynamic handheld electronic devices, according to Blue Planet Software, the company that manages the exclusive licensing rights to the Tetris brand.
“This agreement with Basic Fun opens many new doors for the Tetris brand, and we’re looking forward to working with their innovative and successful team,” said Henk Rogers, president and CEO of Blue Planet Software. “Basic Fun has created and licensed some of the most inventive novelty toys on the market, and Tetris is a truly portable and play-anywhere game — so we’re natural partners. Working together, our fans will have an all new way to take Tetris with them wherever they go.”
Created in 1984 by Russian-born mathematician Alexey Pajitnov, the Tetris game revolutionized puzzle games with distinctive "falling” blocks, called tetriminos, that players could arrange in real time along the bottom of the rectangular playing field, or “matrix,” in order to clear lines. Since then, the game has been translated into more than 50 languages, and it is played in more than 50 countries worldwide. To date, hundreds of millions of units have been sold.
Big Y finalizing purchase of Conn.-based A&P stores
SPRINGFIELD, Mass. Big Y reportedly is closing its deal to acquire seven A&P stores in northern Connecticut.
The Springfield, Mass.-based retailer said the sale will be completed on Nov. 1, according to the Boston Herald. Big Y owns stores in Massachusetts and Connecticut and has served these markets for nearly 75 years.
As previously reported by Drug Store News, grocer A&P announced in September an agreement with Big Y to sell the stores as part of its turnaround strategy.
“We continue to evaluate our operating footprint and its alignment with our turnaround strategy. These seven stores were clearly outside of our core markets, and their sale was necessary,” Sam Martin, president and CEO of A&P, stated at the time.
NeurogesX seeks expanded approval for Qutenza
SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.
NeurogesX announced Monday that it would seek Food and Drug Administration approval for the drug Qutenza (capsaicin) as a treatment for HIV-associated neuropathy, also called HIV-AN or HIV-distal sensory polyneuropathy, in the first half of 2011. The drug, a patch, already is approved for post-herpetic neuralgia. HIV-AN results from injury to sensory neurons by HIV virus proteins, the body’s immune response to the virus and some drugs used to treat it.
“As a company, we are focused on addressing unmet medical needs in pain and have made significant progress toward this goal with the U.S. launch of Qutenza,” NeurogesX president and CEO Anthony DiTonno said. “Our decision to submit a supplemental [application] to address the HIV-AN patient population is important as there are currently no FDA-approved treatments for HIV-AN.”